Loading the section…

IDYA: financial statements from SEC — TradeAlmanac

IDYA

IDEAYA Biosciences, Inc.: financial statements

Company reports as filed with the U.S. Securities and Exchange Commission.

AnnualQuarterly

Income statement

Metric	31/03/2026	31/12/2025	30/09/2025	30/06/2025	31/03/2025	30/09/2024	30/06/2024
Revenue	7M	—	208M	—	—	0	0
Research and development	96M	87M	83M	74M	71M	57M	55M
Selling, general and administrative	19M	—	16M	15M	14M	10M	10M
Operating expenses	115M	—	99M	89M	84M	67M	65M
Operating income	−109M	—	108M	−89M	−84M	−67M	−65M
Net income	−99M	—	119M	−77M	−72M	−52M	−53M
Earnings per share	−1.11	—	1.35	−0.88	−0.82	−0.60	−0.68
Earnings per share, diluted	−1.11	—	1.33	−0.88	−0.82	−0.60	−0.68
Weighted average shares	89M	—	89M	88M	88M	86M	78M
Weighted average shares, diluted	89M	—	90M	88M	88M	86M	78M

Balance sheet

Metric	31/03/2026	31/12/2025	30/09/2025	30/06/2025	31/03/2025	31/12/2024	30/09/2024	30/06/2024
Cash and equivalents	158M	113M	299M	115M	130M	84M	400M	183M
Short-term investments	514M	527M	488M

Cash flow

Metric	31/03/2026	31/03/2025
Operating cash flow	−75M	−60M
Depreciation and amortisation	688,000	600,000
Share-based compensation	15M	10M
Capital expenditure	967,000	1M
Investing cash flow	119M	80M
Financing cash flow	1M

Amounts in USD unless stated otherwise. Data: US exchange trading and company filings with the regulator